iwCAR-T 2019 e-learning

View iwCAR-T 2019 webcasts now!

The 1^st International Workshop on CAR-T (iwCAR-T) took place on October 11–13, 2019, in Miami, FL. The inaugural meeting brought together leading experts in the field to discuss the considerations of this emerging immunotherapy for hematological malignancies.

These e-learning webcasts will help consolidate your knowledge on the key themes surrounding CAR T-cell therapy, including toxicity issues, the evolution of cellular therapies, overcoming resistance mechanisms, as well as its use in CLL, acute leukemias, multiple myeloma, and lymphoma.

You can view each presentation simply by clicking on its title.
Please note that presentations from Session V are unavailable due to unpublished data.

Introduction & Meeting Objectives

▶ The impact of cancer on the host immune system and the immune synapse
John Gribben

▶ CAR-T therapy now and opportunities for the future
David Maloney

Session I: CAR-T in ALL

▶ CAR-T for B-cell ALL and the role of SCT
Noelle Frey

Session II: CAR-T in CLL

▶ CAR T-cells for CLL in the post-chemotherapy era
Saar Gill

▶ CAR T-cells in CLL – update on trials
Tanya Siddiqi

▶ CD19 CAR T-cells with concurrent ibrutinib for ibrutinib-refractory CLL
Jordan Gauthier

Session III: CAR-T in Lymphoma

▶ Axicabtagene ciloleucel for large B-cell lymphoma
Frederick Locke

▶ Update on TRANSCEND NHL-001: lisocabtagene maraleucel
Caron Jacobson

▶ BMT vs CAR-T in second-line DLBCL
Ian Flinn

▶ CAR T-cell approaches to T-cell lymphoma
Matthew Frigault

▶ CAR T-cell therapy in follicular lymphoma
Loretta Nastoupil

Session IV: Toxicity Issues with CAR-T

▶ ASTCT consensus CRS and neurotoxicity definitions and grading
Daniel Lee

▶ Optimization of CRS Management
Rebecca Gardner

▶ CAR T-cell neurotoxicity (ICANS)
Bianca Santomasso

Session VI: CAR-T in AML

▶ Will CAR T-cell therapy have a role in AML?
Saar Gill

▶ Remissions in AML with NKG2D CAR T-cell therapy without a prior preconditioning chemotherapy
Marco Davila

▶ Production and targeting of AML with tumor-reactive T-cells
Marco Davila

Session VII: CAR-T in Multiple Myeloma

▶ Universal SLAMF7-specific CAR T-cells (UCARTCS1) for multiple myeloma
Krina Patel

▶ New targets and technologies for CAR-T: moving beyond ‘state-of-the-art’
Hardikkumar Jetani

▶ LCAR-B38M/JNJ-4528: global CAR-T development perspectives
Tonia Nesheiwat & Jordan Schecter

▶ BCMA-targeting CAR-T: bb2121 and bb21217
Yi Lin

Session VIII: Evolution of Cellular Therapies

▶ Allogeneic CAR T-cells – a reality?
Reuben Benjamin

▶ TCR-like antibody CARs
William Go

Explore More CAR T-Cell Therapy Content on VJHemOnc